Hims & Hers is growing fast — and losing money faster: The telehealth company beat revenue expectations and raised its full-year outlook to $3.1–3.3 billion, but a costly pivot away from compounded GLP-1 drugs helped swing it to… dlvr.it/TTySk8#HimsAndHers#Telehealth
Market wobble: Hims & Hers shares fell after the telehealth group posted widening losses and softer revenue, raising investor concern over growth outlook. Management will cut costs and re-focus strategy - near-term pressure clouds recovery.#HimsAndHers#Stocks
Futures op Wall Street staan paar tienden in de min
Nabeurs zijn er Q1's van #HimsandHers dat niet op een haaientandje meer of minder let in eigen (logaritmische!) grafiek
Hims & Hers is facing class action lawsuits alleging the company failed to protect sensitive patient medical and personal information during a recent data breach. 💊🔐
#HimsAndHersbit.ly/4dfDm2l
Is er nog goed nieuws ook voor aanzienlijk deel van mn timeline 😎
Reuters: "#NovoNordisk has agreed to sell its blockbuster Wegovy and Ozempic drugs through U.S. telehealth company #HimsandHers' platform, ending a legal dispute that erupted last month.